Imatinib (Gleevec)-induced hepatotoxicity

J Clin Gastroenterol. 2005 Jan;39(1):75-7.


Imatinib (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Benzamides
  • Chemical and Drug Induced Liver Injury / etiology*
  • Female
  • Humans
  • Imatinib Mesylate
  • Piperazines / adverse effects*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyrimidines / adverse effects*


  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases